Details

Autor(en) / Beteiligte

• Ponzone, Luca
• Audrito, Valentina
• Landi, Claudia
• Moiso, Enrico
• Levra Levron, Chiara
• Ferrua, Sara
• Savino, Aurora
• Vitale, Nicoletta
• Gasparrini, Massimiliano
• Avalle, Lidia
• Vantaggiato, Lorenza
• Shaba, Enxhi
• Tassone, Beatrice
• Saoncella, Stefania
• Orso, Francesca
• Viavattene, Daniele
• Marina, Eleonora
• Fiorilla, Irene
• Burrone, Giulia
• Abili, Youssef
• Altruda, Fiorella
• Bini, Luca
• Deaglio, Silvia
• Defilippi, Paola
• Menga, Alessio
• Poli, Valeria
• Porporato, Paolo Ettore
• Provero, Paolo
• Raffaelli, Nadia
• Riganti, Chiara
• Taverna, Daniela
• Cavallo, Federica
• Calautti, Enzo

Titel

RICTOR/mTORC2 downregulation in BRAF V600E melanoma cells promotes resistance to BRAF/MEK inhibition

Ist Teil von

• Molecular cancer, 2024-05, Vol.23 (1), p.105

Ort / Verlag

England

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• The main drawback of BRAF/MEK inhibitors (BRAF/MEKi)-based targeted therapy in the management of BRAF-mutated cutaneous metastatic melanoma (MM) is the development of therapeutic resistance. We aimed to assess in this context the role of mTORC2, a signaling complex defined by the presence of the essential RICTOR subunit, regarded as an oncogenic driver in several tumor types, including MM. After analyzing The Cancer Genome Atlas MM patients' database to explore both overall survival and molecular signatures as a function of intra-tumor RICTOR levels, we investigated the effects of RICTOR downregulation in BRAF MM cell lines on their response to BRAF/MEKi. We performed proteomic screening to identify proteins modulated by changes in RICTOR expression, and Seahorse analysis to evaluate the effects of RICTOR depletion on mitochondrial respiration. The combination of BRAFi with drugs targeting proteins and processes emerged in the proteomic screening was carried out on RICTOR-deficient cells in vitro and in a xenograft setting in vivo. Low RICTOR levels in BRAF-mutated MM correlate with a worse clinical outcome. Gene Set Enrichment Analysis of low-RICTOR tumors display gene signatures suggestive of activation of the mitochondrial Electron Transport Chain (ETC) energy production. RICTOR-deficient BRAF cells are intrinsically tolerant to BRAF/MEKi and anticipate the onset of resistance to BRAFi upon prolonged drug exposure. Moreover, in drug-naïve cells we observed a decline in RICTOR expression shortly after BRAFi exposure. In RICTOR-depleted cells, both mitochondrial respiration and expression of nicotinamide phosphoribosyltransferase (NAMPT) are enhanced, and their pharmacological inhibition restores sensitivity to BRAFi. Our work unveils an unforeseen tumor-suppressing role for mTORC2 in the early adaptation phase of BRAF melanoma cells to targeted therapy and identifies the NAMPT-ETC axis as a potential therapeutic vulnerability of low RICTOR tumors. Importantly, our findings indicate that the evaluation of intra-tumor RICTOR levels has a prognostic value in metastatic melanoma and may help to guide therapeutic strategies in a personalized manner.